Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00334880 is registered in ClinicalTrials.gov with New River Pharmaceuticals as lead sponsor.

NCT NCT00334880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00334880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Lead sponsor
New River Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
November 30, 2006
Enrollment
420 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit disorders with hyperactivity, attention deficit hyperactivity disorder, attention deficit hyperactivity disorders